AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6832623 — intervention group
Group type: COMPARATOR
Intervention: Control (water at 37 degrees C)
Number of subjects: 9
Study 30207587 — intervention group
Group type: EXPERIMENTAL
Intervention: Namilumab (20, 50, 80, and 150 mg via subcutaneous injection)
Number of subjects: 122
Study 30207587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 28884242 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose BoNT-A injections at the pretarsal (PT) portion
Number of subjects: 40
Study 28884242 — intervention group
Group type: COMPARATOR
Intervention: Low-dose BoNT-A injections at the preseptal (PS) portion
Number of subjects: 40
Study 25778933 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose combination (paracetamol 1000 mg and ibuprofen 300 mg)
Number of subjects: 159
Study 25778933 — intervention group
Group type: EXPERIMENTAL
Intervention: Half dose combination (paracetamol 500 mg and ibuprofen 150 mg)
Number of subjects: 159
Study 25778933 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarter dose combination (paracetamol 250 mg and ibuprofen 75 mg)
Number of subjects: 159
Study 25778933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 25778933 — intervention group
Group type: EXPERIMENTAL
Intervention: All combination doses
Number of subjects: 159
Study 23979345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention (BEE×1.1×1.3-1.5 kcal/kg/day)
Number of subjects: 50
Study 23979345 — intervention group
Group type: COMPARATOR
Intervention: Control group (BEE×1.1×1.1-1.3 kcal/kg/day)
Number of subjects: 50
Study 21748479 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavyweight polypropylene mesh (HWM) (105 g/m(2))
Number of subjects: 32
Study 21748479 — intervention group
Group type: COMPARATOR
Intervention: Lightweight polypropylene mesh (LWM) (28 g/m(2))
Number of subjects: 32
Study 18762940 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS)
Number of subjects: 100
Study 18762940 — intervention group
Group type: COMPARATOR
Intervention: Conventional standard procedure
Number of subjects: 100
Study 16728451 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME (20 mM)
Number of subjects: 8
Study 16728451 — intervention group
Group type: COMPARATOR
Intervention: Local Cooling (34-24 degrees C) for 35 min
Number of subjects: 8
Study 16728451 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME
Number of subjects: 8
Study 16728451 — intervention group
Group type: EXPERIMENTAL
Intervention: BT + L-NAME
Number of subjects: 8
Study 16728451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside (SNP 10 microM)
Number of subjects: 8
Study 11950112 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction condition (nurses used stimuli to divert infants' attention)
Number of subjects: 90
Study 11950112 — intervention group
Group type: COMPARATOR
Intervention: Typical care condition
Number of subjects: 90
Study 10074644 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (4 micrograms/kg/min)
Number of subjects: 30
Study 10074644 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (1 microgram/kg/min increasing to 2 micrograms/kg/min)
Number of subjects: 30
Study 10074644 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose 5%)
Number of subjects: 30
Study 8834657 — intervention group
Group type: EXPERIMENTAL
Intervention: rhu-EPO treatment for 12 months
Number of subjects: 27
Study 8834657 — intervention group
Group type: COMPARATOR
Intervention: non-EPO group (clinical monitoring)
Number of subjects: 27
Study 8834657 — intervention group
Group type: COMPARATOR
Intervention: HD group (haematocrit > or = 30% without rhu-EPO therapy)
Number of subjects: 27
Study 2341262 — intervention group
Group type: EXPERIMENTAL
Intervention: Backrest position at 20 degrees
Number of subjects: 30
Study 2341262 — intervention group
Group type: EXPERIMENTAL
Intervention: Backrest position at 40 degrees
Number of subjects: 30
Study 2341262 — intervention group
Group type: COMPARATOR
Intervention: Flat position (control)
Number of subjects: 30
Study 7001038 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed drug combination of chloroquine and paracetamol (single dose)
Number of subjects: 154
Study 7001038 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine and paracetamol given as separate tablets (extended over 3 days or longer)
Number of subjects: 154
Study 6343259 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg twice daily
Number of subjects: 11
Study 6343259 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg once daily
Number of subjects: 11
Study 6343259 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg once daily
Number of subjects: 11
Study 6343259 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg once daily
Number of subjects: 11
Study 6343259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30974955 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 85
Study 30974955 — intervention group
Group type: COMPARATOR
Intervention: Ankle-Foot Orthoses (AFO)
Number of subjects: 85
Study 29863586 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine
Number of subjects: 22
Study 29863586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 29863586 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 27846868 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 2045
Study 27846868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2045
Study 24647158 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT/LV
Number of subjects: 180
Study 24647158 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 180
Study 22571394 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/benazepril 10/20 mg/day
Number of subjects: 1013
Study 22571394 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/benazepril 10/40 mg/day
Number of subjects: 1013
Study 22571394 — intervention group
Group type: COMPARATOR
Intervention: Benazepril 40 mg/day
Number of subjects: 1013
Study 22571394 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg/day
Number of subjects: 1013
Study 19875481 — intervention group
Group type: EXPERIMENTAL
Intervention: IKK/NF-kappaB pathway activity measured by IkappaBbeta to p65 ratio
Number of subjects: 181
Study 19875481 — intervention group
Group type: EXPERIMENTAL
Intervention: IKK/NF-kappaB pathway activity
Number of subjects: 181
Study 18803988 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mg nicotine lozenge
Number of subjects: 1144
Study 18803988 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mg nicotine lozenge
Number of subjects: 1144
Study 18803988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1144
Study 18803988 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional distress scores
Number of subjects: 1144
Study 18803988 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving scores
Number of subjects: 1144
Study 18803988 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional distress
Number of subjects: 1144
Study 18803988 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving
Number of subjects: 1144
Study 16204708 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe CAD
Number of subjects: 103
Study 16204708 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 103
Study 16204708 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular Hypertrophy (LVH)
Number of subjects: 103
Study 16204708 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia Score
Number of subjects: 103
Study 16204708 — intervention group
Group type: EXPERIMENTAL
Intervention: LVH in patients with severe CAD
Number of subjects: 103
Study 16204708 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes in patients with severe CAD
Number of subjects: 103
Study 12456454 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg IV
Number of subjects: 150
Study 12456454 — intervention group
Group type: COMPARATOR
Intervention: normal saline IV (placebo)
Number of subjects: 150
Study 10582974 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum alpha‐tocopherol
Number of subjects: 28519
Study 10582974 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum beta‐carotene
Number of subjects: 28519
Study 10582974 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure > or = 160 mm Hg
Number of subjects: 28519
Study 10582974 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum total cholesterol > or = 7.0 mmol/L
Number of subjects: 28519
Study 10582974 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum HDL cholesterol > or = 0.85 mmol/L
Number of subjects: 28519
Study 10582974 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum total cholesterol
Number of subjects: 28519
Study 8618185 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO treatment with protein intake up to 3.1 gm/kg per day
Number of subjects: 20
Study 8618185 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO treatment
Number of subjects: 20
Study 8618185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1753168 — intervention group
Group type: EXPERIMENTAL
Intervention: Coculture with passaged human tubal ampullary epithelial cells
Number of subjects: 32
Study 1753168 — intervention group
Group type: COMPARATOR
Intervention: Culture medium alone
Number of subjects: 32
Study 7085556 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized triamcinolone acetonide (200 micrograms inhalations, four times daily for 12 weeks)
Number of subjects: 30
Study 7085556 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized triamcinolone acetonide
Number of subjects: 30
Study 31264757 — intervention group
Group type: EXPERIMENTAL
Intervention: Efpeglenatide 4 mg once weekly
Number of subjects: 297
Study 31264757 — intervention group
Group type: EXPERIMENTAL
Intervention: Efpeglenatide 6 mg once weekly
Number of subjects: 297
Study 31264757 — intervention group
Group type: EXPERIMENTAL
Intervention: Efpeglenatide 6 mg once every 2 weeks
Number of subjects: 297
Study 31264757 — intervention group
Group type: EXPERIMENTAL
Intervention: Efpeglenatide 8 mg once every 2 weeks
Number of subjects: 297
Study 31264757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 30389952 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean SAT thickness measured from eight standardised ultrasound sites
Number of subjects: 10
Study 30389952 — intervention group
Group type: COMPARATOR
Intervention: Mean SAT thickness measured from 216 randomly selected sites
Number of subjects: 10
Study 26643052 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based constraint-induced therapy (CIT) for 4 weeks
Number of subjects: 23
Study 24440221 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 24
Study 24440221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24440221 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term infliximab
Number of subjects: 24
Study 24440221 — intervention group
Group type: COMPARATOR
Intervention: No infliximab
Number of subjects: 24
Study 24440221 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab for most of the follow-up period
Number of subjects: 24
Study 24440221 — intervention group
Group type: COMPARATOR
Intervention: Infliximab for shorter periods
Number of subjects: 24
Study 21385196 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast for 4-8 weeks
Number of subjects: 252
Study 20370845 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone prolonged release/naloxone prolonged release
Number of subjects: 379
Study 17547746 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting corticosteroid injection
Number of subjects: 90
Study 17547746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 17547746 — intervention group
Group type: COMPARATOR
Intervention: Non-COPD control group
Number of subjects: 90
Study 16354439 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual psychotherapy
Number of subjects: 48
Study 16354439 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 48
Study 16354439 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 48
Study 12092034 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinococcus granulosus infection (cystic echinococcosis)
Number of subjects: 0
Study 12092034 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinococcus multilocularis infection (alveolar echinococcosis)
Number of subjects: 0
Study 10539748 — intervention group
Group type: COMPARATOR
Intervention: 0 micromol RE/d
Number of subjects: 26
Study 10539748 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.2 micromol RE/d
Number of subjects: 26
Study 10539748 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.5 micromol RE/d
Number of subjects: 26
Study 8001370 — intervention group
Group type: COMPARATOR
Intervention: Age group > 80 years
Number of subjects: 774
Study 8001370 — intervention group
Group type: COMPARATOR
Intervention: Age group ≤ 45 years
Number of subjects: 774
Study 8001370 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 774
Study 8001370 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with good neurologic function
Number of subjects: 774
Study 8001370 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a factor
Number of subjects: 774
Study 8001370 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of good neurologic recovery
Number of subjects: 774
Study 2339011 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS-fentanyl
Number of subjects: 40
Study 2339011 — intervention group
Group type: COMPARATOR
Intervention: TTS-placebo
Number of subjects: 40
Study 231374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ACTH (0.5 mg) for 4 days
Number of subjects: 32
Study 231374 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 days
Number of subjects: 32
Study 31173422 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-and-behaviour-change intervention (VBC)
Number of subjects: 9325
Study 31173422 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-only (V)
Number of subjects: 9325
Study 31173422 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 9325
Study 31173422 — intervention group
Group type: EXPERIMENTAL
Intervention: VBC
Number of subjects: 9325
Study 31173422 — intervention group
Group type: EXPERIMENTAL
Intervention: V
Number of subjects: 9325
Study 27885469 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA (netupitant 300 mg and palonosetron 0.50 mg)
Number of subjects: 1455
Study 27885469 — intervention group
Group type: COMPARATOR
Intervention: Oral PALO (palonosetron 0.50 mg)
Number of subjects: 1455
Study 26008855 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (simulated altitude of 3,500 m)
Number of subjects: 32
Study 26008855 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (control group)
Number of subjects: 32
Study 26008855 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Hypoxia and Normoxia)
Number of subjects: 32
Study 24063779 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetics containing purified bee venom (PBV)
Number of subjects: 12
Study 24063779 — intervention group
Group type: COMPARATOR
Intervention: Cosmetics without purified bee venom (PBV)
Number of subjects: 12
Study 21725873 — intervention group
Group type: EXPERIMENTAL
Intervention: Pu'er tea extract
Number of subjects: 90
Study 21725873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 19019046 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful diabetic peripheral neuropathy (DPN)
Number of subjects: 401
Study 16878063 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (corticoid)
Number of subjects: 73
Study 16878063 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (NSAID)
Number of subjects: 73
Study 12633482 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Acute Care (PAC) coordinator
Number of subjects: 598
Study 12633482 — intervention group
Group type: COMPARATOR
Intervention: Usual discharge planning (control)
Number of subjects: 598
Study 10714480 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP-HFA (HFA 134a)
Number of subjects: 229
Study 10714480 — intervention group
Group type: COMPARATOR
Intervention: BDP-CFC (CFC)
Number of subjects: 229
Study 8823470 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus 13‐cis‐retinoic acid (RA) at a dosage of 1 mg/kg/day for 1 month
Number of subjects: 40
Study 8823470 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy alone
Number of subjects: 40
Study 8823470 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus 13‐cis‐retinoic acid (RA)
Number of subjects: 40
Study 1396064 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol HCL capsule (THC)
Number of subjects: 51
Study 1396064 — intervention group
Group type: COMPARATOR
Intervention: Control drugs (AT-237 and Anfendein)
Number of subjects: 51
Study 4079660 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-desamino-8-D-arginine vasopressin, administered intranasally, double-blind, prior to ethanol ingestion
Number of subjects: 26
Study 4079660 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered intranasally, double-blind, prior to ethanol ingestion
Number of subjects: 26
Study 30802313 — intervention group
Group type: EXPERIMENTAL
Intervention: WoTWoD cultural respect framework
Number of subjects: 135
Study 30802313 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135
Study 30204698 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 2947
Study 30204698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2947
Study 26764061 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT Angiography (CCTA)
Number of subjects: 500
Study 26764061 — intervention group
Group type: COMPARATOR
Intervention: Standard Optimal Care (SOC)
Number of subjects: 500
Study 25244390 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment motivation (being in action vs. preaction)
Number of subjects: 392
Study 25244390 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment motivation
Number of subjects: 392
Study 22647933 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 345
Study 22106975 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg
Number of subjects: 0
Study 22106975 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg
Number of subjects: 0
Study 22106975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19195916 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiglucerase infused every 4 weeks (Q4)
Number of subjects: 95
Study 19195916 — intervention group
Group type: COMPARATOR
Intervention: Imiglucerase infused every 2 weeks (Q2)
Number of subjects: 95
Study 17004259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion (CsA-ME)
Number of subjects: 495
Study 17004259 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 495
Study 12752346 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 0.5 mg/kg
Number of subjects: 35
Study 12752346 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 1.0 mg/kg
Number of subjects: 35
Study 12752346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 11069316 — intervention group
Group type: EXPERIMENTAL
Intervention: alendronate 10 mg o.d.
Number of subjects: 76
Study 11069316 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 650 mg q. d.s.
Number of subjects: 76
Study 11069316 — intervention group
Group type: COMPARATOR
Intervention: placebo o.d.
Number of subjects: 76
Study 10225757 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE)
Number of subjects: 383
Study 10225757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin (IVIg)
Number of subjects: 383
Study 10225757 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Exchange followed by Intravenous Immunoglobulin (PE + IVIg)
Number of subjects: 383
Study 8038352 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine (20 mg b.d.)
Number of subjects: 12
Study 8038352 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine (400 mg b.d.)
Number of subjects: 12
Study 8038352 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine (150 mg b.d.)
Number of subjects: 12
Study 8038352 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 2902494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily for two years or until death
Number of subjects: 181
Study 2902494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 2902494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 181
Study 29454393 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from an electronic audit and feedback dashboard providing ICU's own performance, median and top 10% peer performance, and improvement recommendations.
Number of subjects: 72
Study 29454393 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from an electronic audit and feedback dashboard.
Number of subjects: 72
Study 28111861 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual cup (MC)
Number of subjects: 51
Study 28111861 — intervention group
Group type: COMPARATOR
Intervention: Endocervical swab (ECS)
Number of subjects: 51
Study 28111861 — intervention group
Group type: COMPARATOR
Intervention: ECS-enriched cervicovaginal lavage (eCVL)
Number of subjects: 51
Study 25887362 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss only (D)
Number of subjects: 454
Study 25887362 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss plus exercise (D + E)
Number of subjects: 454
Study 25887362 — intervention group
Group type: COMPARATOR
Intervention: Exercise-only control (E)
Number of subjects: 454
Study 25066942 — intervention group
Group type: EXPERIMENTAL
Intervention: Rusie Dutton
Number of subjects: 50
Study 25066942 — intervention group
Group type: COMPARATOR
Intervention: Control (waiting list)
Number of subjects: 50